Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Unlike your bleach Brilacidin was well tolerated. “Based on analyses of our Phase 2 trial results, Brilacidin showed promising treatment effects in NEWS2 clinical improvement scores and among patients with the most elevated biomarker levels,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “These results, along with observations on the compassionate use of Brilacidin in COVID-19 related to dosing, as well as data being generated from ongoing scientific collaborations, are informing paths forward for our Brilacidin antiviral program.

Promising is what we need. Most covid treatments showed no promise.